oradrenalin versus Midodrin-Octerotid in Hepatorenal Syndrome
Phase 3
- Conditions
- Hepatorenal Syndrome type 1 & 2.Hepatorenal Syndrome
- Registration Number
- IRCT201107217085N1
- Lead Sponsor
- Vice Chancellery for Reserch and Technology, Isfahan University of Medical Sciences, Isfahan, Iran
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
Hepatorenal syndrom patients … Exclusion criteria: Improvement of renal function after volume expansion; history of infection, nephrotoxic drug usage or volume loss in recent week; contraindication to Noradrenalin, Midodrine or Octreotide; recent history of gastrointestinal bleeding; severe hepatic encephalopathy; hepatocellular carcinoma; platelet counts lower than 25000 per microliters; international normalized ratio (INR) more than 5; acute coronary syndrome
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum ceatinine. Timepoint: Before the study and every day during the study. Method of measurement: laboratory method.
- Secondary Outcome Measures
Name Time Method Systolic and diastolic pressure. Timepoint: Before the study and every 4 hours during the study. Method of measurement: sphygmomanometer.;Urinary output. Timepoint: Before the study and every day during the study. Method of measurement: Collecting scaled bag.;Serum and urinary sodium. Timepoint: Before the study and every day during the study. Method of measurement: Laboratory method.;Glomerular filtration rate. Timepoint: Before the study and every day during the study. Method of measurement: Cockroft-Gault formula.